$NSPR

InspireMD, Inc.

InspireMD develops and commercializes medical devices for carotid artery disease and other vascular conditions. Its commercial products use the CGuard carotid stent technology, which combines a self-expanding stent with a MicroNet mesh sleeve designed to limit plaque debris from entering the bloodstream. CGuard EPS is sold outside the United States through distributors, while CGuard Prime is marketed exclusively in the United States through InspireMD’s direct salesforce. The company is also developing SwitchGuard, a neuroprotection system intended to provide flow reversal during carotid procedures. InspireMD makes money by commercializing its medical devices. CGuard EPS is marketed in over 30 countries outside the United States, and CGuard Prime is sold in the United States. The company’s global headquarters are in Miami, Florida.

6
2
8

No SEC Form 4 filings for $NSPR in the last 30 days.

See all $NSPR insider activity →
Med

InspireMD, Inc. (NSPR): Entry into a Material Definitive Agreement

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 InspireMD Announces Pricing of $37.5 Million Public Offering Miami, FL -- November 13, 2026 — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the pricing

Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals

InspireMD (NSPR) received FDA approval for its TCAR stent, while Eli Lilly (LLY) and Bayer (BAYRY) secured approvals for obesity and stroke drugs. Johnson & Johnson (JNJ) won FDA approval for a head and neck cancer treatment. Meanwhile, Sionna (SION), Nano-X (NNOX), and Coherus (CHRS) announced workforce reductions. Pfizer (PFE) and Blackstone agreed to co-fund an obesity drug. Key stock prices were reported.

InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens

InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.

NSPR sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 16 news stories mentioning NSPR (InspireMD, Inc.). Coverage has skewed bearish: 6 bullish, 2 neutral, and 8 bearish.

Recent NSPR coverage spans corporate actions, earnings and regulation.

What's driving NSPR

AlphAI scores every news story that mentions NSPR with an AI model for sentiment and relevance, and aggregates insider trades from InspireMD, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NSPR

Score
$NSPRMedOffering· $37.5M · priced

InspireMD, Inc. (NSPR): Entry into a Material Definitive Agreement

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 InspireMD Announces Pricing of $37.5 Million Public Offering Miami, FL -- November 13, 2026 — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the pricing

Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals

InspireMD (NSPR) received FDA approval for its TCAR stent, while Eli Lilly (LLY) and Bayer (BAYRY) secured approvals for obesity and stroke drugs. Johnson & Johnson (JNJ) won FDA approval for a head and neck cancer treatment. Meanwhile, Sionna (SION), Nano-X (NNOX), and Coherus (CHRS) announced workforce reductions. Pfizer (PFE) and Blackstone agreed to co-fund an obesity drug. Key stock prices were reported.

InspireMD Inc (NSPR) (Q3 2026) Earnings Call Highlights: FDA Nod for CGuard Prime Reopens

InspireMD (NSPR) reported Q3 2026 revenue of $2.2M, down 11% YoY, with gross margin at 10.7%. The company received FDA approval for CGuard Prime, expecting immediate sales due to pent-up demand. Cash position is $19.2M, with potential $10M from warrant exercises. A workforce reduction cut expenses by 27%. The US market opportunity is expanded by 40,000 annual procedures. No formal guidance was provided.

$NSPRHighEarnings

InspireMD Reports Third Quarter 2026 Financial Results

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 InspireMD Reports Third Quarter 2026 Financial Results - Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call to

$NSPRHighAI 8/10Clinical / regulatory· FDA approval

InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures

InspireMD, Inc. (NSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 InspireMD Announces FDA Approval of the CGuard ® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures - Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR

InspireMD Aligns Warrants With Anticipated CGuard Prime FDA Decision

InspireMD (NSPR) amended Series J and K warrants, potentially raising $11M if exercised. The changes align with the expected 2026 FDA decision on its CGuard Prime stent. The warrants cover 4.8M and 9.5M shares respectively, with an exercise price expiring by May 2028 or 20 days post-FDA approval. The company aims to use proceeds for CGuard Prime launch and pipeline initiatives. NSPR stock is up 0.83% at $0.77.

InspireMD Q2 2026 Earnings: Revenue Misses $1.77 Million Estimate

InspireMD (NSPR) reported Q2 2026 revenue of $1.77M, missing estimates of $2.54M, and a net loss of $0.17 per share, beating expectations. Shares fell 7.06% due to revenue shortfall and U.S. recall impacts. The company expects FDA decisions on key products later in 2026. International revenue rose 21% YoY, while U.S. revenue was negative due to recall-related credits.

InspireMD, Inc. Q2 2026 Earnings Call Summary

InspireMD reported Q2 2026 results, citing flat revenue from a voluntary recall of its CGuard Prime 135 delivery system. Management said $734,000 in customer credits offset underlying U.S. growth, with a $612,000 inventory impairment and negative reported gross margin of 43.7%. It cut staff 20% and expects about $9M annual savings. FDA decisions for CGuard Prime 80 (TCAR) and CGuard CAS are targeted for Q4 2026, with Prime 135 reentry in H1 2027.

Related tickers